

CHIMERIX INC  
Form 8-K  
October 11, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**July 24, 2017**

Date of Report (Date of earliest event reported)

**Chimerix, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

**001-35867**

**33-0903395**

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

**2505 Meridian Parkway, Suite 100**

**Durham, NC**

**27713**

(Address of principal executive offices)

(Zip Code)

**Registrant's telephone number, including area code: (919) 806-1074**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

“Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

“Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. “

**Item 8.01**

**Other Events.**

On July 24, 2017, August 25, 2017, September 22, 2017 and September 28, 2017, Chimerix, Inc. entered into amendments No. 41, No. 42, No. 43 and No. 44 (collectively, the “**Amendments**”), respectively, to its contract with the Biomedical Advanced Research and Development Authority (“**BARDA**”) for the development of brincidofovir as a potential medical countermeasure for smallpox.

The Amendments modify the period of performance for contracted work being performed under Option Segment 2 and adjust BARDA’s obligations as a result of unused funding under the previously completed Base Segment.

The foregoing summary of the Amendments does not purport to be complete and is qualified in its entirety by reference to the Amendments, copies of which are attached hereto as exhibits 99.1, 99.2, 99.3 and 99.4.

**Item 9.01**

**Financial Statements and Exhibits.**

(d)Exhibits

Exhibit No. Description

99.1 Contract modification No. 41, dated July 24, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended.

99.2 Contract modification No. 42, dated August 25, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended.

99.3 Contract modification No. 43, dated September 22, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended.

99.4\* Contract modification No. 44, dated September 28, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended.

\* Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Chimerix, Inc.**

Dated: October 11, 2017

By: /s/ Timothy W. Trost  
Timothy W. Trost  
Senior Vice President,  
Chief Financial  
Officer and Corporate  
Secretary